Premium
Effect of combined testosterone and estradiol‐17β treatment on the metabolism of E 2 in the prostate and liver of noble rats
Author(s) -
Lane Kate E.,
Ricci Mary Jo,
Ho ShukMei
Publication year - 1997
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19970301)30:4<256::aid-pros5>3.0.co;2-j
Subject(s) - microsome , endocrinology , medicine , prostate , estrogen , testosterone (patch) , chemistry , cancer , biochemistry , in vitro
BACKGROUND Long‐term treatment of Noble (NBL) rats with testosterone (T) and estradiol‐17β (E 2 ) induces dysplasia in the dorsolateral lobe (DLP) but not in the ventral lobe (VP) of the rat prostate. The aim of this study was to determine whether metabolic conversion of E 2 to catechol estrogens (CEs), which are potentially genotoxic, is a mechanism of estrogen carcinogenicity in this tissue. METHODS Male NBL rats were treated simultaneously with T and E 2 , or left untreated, for 16 weeks after which time the liver, VP, and DLP were excised for microsomal preparations. 3 H‐E 2 metabolites generated in microsomal incubates were separated by high‐performance liquid chromatography (HPLC) and identified by coelution with known E 2 metabolites. RESULTS 2‐ and 4‐hydroxyestrogens were detected at high levels in hepatic microsomal incubates, and at extremely low levels in prostatic microsomal incubates. T + E 2 treatment of rats did not increase the formation of these prostatic and hepatic metabolites. CONCLUSIONS These results do not support CE formation as a mediating step in estrogen‐induced tumorigenesis in the rat prostate. Prostate 30:256–262, 1997. © 1997 Wiley‐Liss, Inc.